Aldeyra Therapeutics Logo
US01438T1060
A111X8
ALDX

Aldeyra Therapeutics

Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 8,81 € (+1298,41 %). La mediana es de 9,11 € (+1346,03 %).

Comprar
  18
Mantener
  1
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Aldeyra adds Darlene Deptula-Hicks to board of directors

    Aldeyra has appointed Darlene Deptula-Hicks to its board of directors; she brings more than 30 years of experience in the biotech sector and expertise as a finance executive at public and private life-science companies. Deptula-Hicks is currently interim CFO of Normunity and was previously CFO of F-star Therapeutics; her experience with IPOs, capital raising and M&A is expected to support potential commercialization of Aldeyra’s therapies. Aldeyra is developing RASP modulators and is advancing reproxalap and ADX-2191 in late-stage development; the company has a market capitalization of $104 million, a current ratio of 2.72, and its stock has traded well below last year’s level since the start of the year, while analyst price targets remain between $2 and $13. » Más en de.investing.com


  • Aldeyra Therapeutics repays $15 million loan and terminates credit facility

    Aldeyra Therapeutics repaid all outstanding liabilities of $15 million on April 1, thereby terminating the loan agreement with Hercules Capital in accordance with the contract. The company reports a balance sheet with more cash than debt and expects that cash, cash equivalents and marketable securities will fund operations through 2028. At the same time, Aldeyra faces regulatory pressure following an FDA Complete Response Letter for Reproxalap; analyst reactions are mixed (BTIG: buy, price target $9.00; H.C. Wainwright: neutral, price target $2.00). The stock trades well below last year’s level, reflecting the ongoing uncertainties. » Más en de.investing.com


  • Aldeyra Therapeutics: chief development officer Dr. Stephen G. Machatha to resign by March 2026

    Aldeyra Therapeutics announced that Dr. Stephen G. Machatha has voluntarily resigned as chief development officer; his last day will be no later than March 31, 2026. The company and Machatha reached a transition agreement under which he will remain employed through his departure, continue to receive his base salary and benefits, and have outstanding equity awards remain unchanged. As part of the agreement, Machatha will receive a one‑time payment of $88,000 and may receive an additional $88,000 if he signs further release agreements after leaving. The company emphasized that the resignation is not the result of any disagreement with management or the board. » Más en de.investing.com


  • Aldeyra receives EMA orphan drug status for ADX-2191 to treat rare retinal diseases

    Aldeyra Therapeutics has been granted orphan drug status by the European Medicines Agency for ADX-2191 for the treatment of inherited retinal dystrophies, including retinitis pigmentosa. The company will benefit from regulatory advantages and plans to conduct further clinical trials, while its financial position is described as solid. Additionally, progress has been reported in the development and approval applications of other medications. » Más en de.investing.com


  • Aldeyra receives positive FDA feedback for eye drug Reproxalap

    Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted the resubmitted approval application for its eye drug Reproxalap, intended for the treatment of dry eye disease. The FDA's decision is expected by December 16, 2025, following the submission of additional clinical data. Analysts remain optimistic about the stock, and the company is financially well positioned to continue its development programs. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, Aldeyra Therapeutics tuvo unos ingresos de 0 € y un beneficio neto de -3,32 M €
(EUR) septiembre de 2026
YoY
Ingresos 0 -
Beneficio bruto 0 -
Beneficio neto -3,32 M 49,29 %
EBITDA -3,19 M 47,71 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
38,23 M €
Número de acciones
60,36 M
Máximo/mínimo de 52 semanas
5,40 € - 0,48 €
Dividendos No
Beta
1,29
Ratio P/E
-2,18
Ratio PEG
-0,02
Ratio P/B
0,00
Ratio P/S
0,00

Perfil de la empresa

Aldeyra Therapeutics, Inc., una empresa de biotecnología, desarrolla y comercializa medicamentos para enfermedades oculares y sistémicas de origen inmunomediado. El candidato principal de la compañía es reproxalap, un modulador de especies aldehído reactivas (RASP, por sus siglas en inglés), que se encuentra en ensayo clínico de fase III para el tratamiento de la sequedad ocular y la conjuntivitis alérgica. También desarrolla ADX-629, un modulador RASP de primera clase en su categoría, de administración oral, que se encuentra en ensayo clínico de fase II para la psoriasis, el asma y la COVID-19; y ADX-2191, un inhibidor de la dihidrofolato reductasa que se encuentra en fase III para la prevención de la vitreorretinopatía proliferativa, y en ensayo clínico de fase II para el tratamiento de la retinitis pigmentosa, así como para el tratamiento del linfoma vitreorretiniano primario. La compañía tiene un acuerdo de licencia con Madrigal Pharmaceuticals, Inc. para el desarrollo de ADX-1612, que inhibe la chaperona proteica para el tratamiento de enfermedades inflamatorias. La empresa se conocía anteriormente como Aldexa Therapeutics, Inc. y cambió su nombre a Aldeyra Therapeutics, Inc. en marzo de 2014. Aldeyra Therapeutics, Inc. se constituyó en 2004 y tiene su sede en Lexington, Massachusetts.

Nombre
Aldeyra Therapeutics
CEO
Todd C. Brady
Sede Lexington, ma
Estados Unidos
Sitio web
Sector
Salud
Industria
Biotecnología
Salida a bolsa
02/05/2014
Empleados 6

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
ALDX
Frankfurt
137.F
Düsseldorf
137.DU
München
137.MU
🍪

Parqet  usa cookies. Más información